NYSE · CIK 0001136869 · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
ZIMMER BIOMET HOLDINGS, INC.
ZBH chart by TradingView
PRICE HISTORY
LIVE · NYSEZBH chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $8.2B
- EBITDA
- $2.2B
- FREE CASH FLOW
- $1.5B
- EPS
- $3.55
- GROSS MARGIN
- 69.71%
- ROIC
- 3.59%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
20.6x
-71%12.8x653.0x
⤢
P / SALES (TTM)
2.0x
-42%2.0x5.5x
⤢
P / BOOK
1.3x
-50%1.3x2.6x
⤢
EV / EBITDA (TTM)
10.2x
-48%10.2x39.2x
⤢
EV / REVENUE (TTM)
2.8x
-42%2.8x6.7x
⤢
FCF YIELD (TTM)
9.18%
+4.1pp2.76%9.18%
⤢
DIVIDEND YIELD (TTM)
1.12%
+0.4pp0.61%1.12%
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$2.2B
+19%⤢
EBITDA (DERIVED)
$0.6B
+66%⤢
NET INCOME
$0.2B
+25%⤢
EPS (DILUTED)
$1.03
+31%⤢
REVENUE GROWTH YOY
4.80%
+0.8pp-44.10%49.56%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
18.08%
+1.9pp-5.86%33.91%
⤢
RETURN ON CAPITAL
4.10%
+2.4pp-1.93%8.49%
⤢
RETURN ON EQUITY (TTM)
6.39%
+2.7pp-3.36%15.46%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN70.81%
OPERATING MARGIN14.98%
NET MARGIN9.11%
FCF MARGIN18.08%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.4B
+33%⤢
STOCK-BASED COMP
$0.0B
+62%⤢
CAPITAL EXPENDITURE
$0.1B
-4%⤢
SHARES OUTSTANDING
0.19B
-5%⤢
DIVIDEND / SHARE
$0.24
+0%BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.4B
-14%⤢
TOTAL DEBT
$7.5B
-35%⤢
DEBT / EBITDA (TTM)
3.2x
-48%2.5x8.6x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 106.91%INSIDERS 0.15%OTHER / RETAIL 0.00%1,263 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Dodge & Cox Inc. | 12.17% | 23.5M | $2.27B | +0.1% |
| Blackrock Inc. | 7.93% | 15.3M | $1.48B | -1.7% |
| Harris Associates L.P. | 6.70% | 13.0M | $1.25B | +5.7% |
| Vanguard Capital Management LLC | 6.61% | 12.8M | $1.24B | NEW |
| Capital International Investors | 4.71% | 9.1M | $880.5M | +27.9% |
| State Street Corporation | 4.56% | 8.8M | $852.1M | -0.0% |
| Vanguard Portfolio Management LLC | 4.47% | 8.7M | $835.2M | NEW |
| Price (T.Rowe) Associates Inc | 4.14% | 8.0M | $772.4M | -41.3% |
| Franklin Resources, Inc. | 2.82% | 5.5M | $526.5M | -18.5% |
| Geode Capital Management, LLC | 2.78% | 5.4M | $519.4M | +2.8% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.